Bitter Pill_final accepted version for SRO.pdf (524.42 kB)
A bitter pill? Institutional corruption and the challenge of antibribery compliance in the pharmaceutical sector
journal contribution
posted on 2023-06-09, 05:29 authored by Elizabeth David-BarrettElizabeth David-Barrett, Basak Yakis-Douglas, Amanda Moss-Cowan, Yen NguyenWe investigate why top-down directives aimed at eradicating corruption are ineffective at altering on-the-ground practices for organizations that have adopted industry-wide “gold standards” to prevent bribery and corruption. Using interview and focus group data collected from leading multinational pharmaceutical firms, we unearth antecedents contributing to organizations’ systemic failure to embed their anticorruption policies in business practice. We identify two tensions that contribute to this disconnect: a culture clash between global and local norms, especially in emerging markets and a similar disconnect between the compliance and commercial functions. To overcome these tensions, we suggest that organizations are likely to find it easier to implement a no gifts policy if they cease to rely on local agents embedded in local norms and that there needs to be strong evidence of board-level commitment to antibribery programs, innovative ways of incentivizing compliant behavior, and a fundamental rethinking of organizations’ business model and remuneration practices.
History
Publication status
- Published
File Version
- Accepted version
Journal
Journal of Management InquiryISSN
1056-4926Publisher
SAGE PublicationsExternal DOI
Issue
3Volume
26Page range
326-347Department affiliated with
- Politics Publications
Research groups affiliated with
- Sussex Centre for the Study of Corruption Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2017-03-16First Open Access (FOA) Date
2017-03-16First Compliant Deposit (FCD) Date
2017-03-16Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC